Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 27;12(3):e008585. doi: 10.1136/jitc-2023-008585

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Kaplan-Meier curves for progression-free survival and overall survival and the timeline according to treatments in the clinical study. (A) Progression-free survival. (B) Overall survival. (C) Treatment timeline in each patient. C/GC, cetuximab/gemcitabine/carboplatin; cohort 1, SNK01 (4×10⁹ cells/dose)+gemcitabine/carboplatin; cohort 2, SNK01 (4×10⁹ cells/dose)+cetuximab/gemcitabine/carboplatin; cohort 3, SNK01 (6×10⁹ cells/dose)+gemcitabine/carboplatin; cohort 4, SNK01 (6×10⁹ cells/dose)+cetuximab/gemcitabine/carboplatin; GC, gemcitabine/carboplatin; PR, partial response; SD, stable disease;